53 related articles for article (PubMed ID: 20723392)
1. [Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways in Non-small Cell Lung Cancer Therapy.].
Nan J; Liu Q; Ding Y; Zhang Z; Gao AC; Zhou Q
Zhongguo Fei Ai Za Zhi; 2009 Dec; 12(12):1316-24. PubMed ID: 20723392
[No Abstract] [Full Text] [Related]
2. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
3. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
5. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Socinski MA
Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
[TBL] [Abstract][Full Text] [Related]
6. Expression of thymosin beta10 and its role in non-small cell lung cancer.
Gu Y; Wang C; Wang Y; Qiu X; Wang E
Hum Pathol; 2009 Jan; 40(1):117-24. PubMed ID: 18789485
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer.
Lin Q; Li M; Shen ZY; Xiong LW; Pan XF; Gen JF; Bao GL; Sha HF; Feng JX; Ji CY; Chen M
Jpn J Clin Oncol; 2010 Jul; 40(7):670-6. PubMed ID: 20382636
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa.
Hong JY; Chung HJ; Lee HJ; Park HJ; Lee SK
J Nat Prod; 2011 Oct; 74(10):2102-8. PubMed ID: 21916433
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor signaling in non-small-cell lung cancer.
Semrad TJ; Mack PC
Clin Lung Cancer; 2012 Mar; 13(2):90-5. PubMed ID: 21959109
[TBL] [Abstract][Full Text] [Related]
11. New molecular targeted therapies integrated with radiation therapy in lung cancer.
Provencio M; Sánchez A; Garrido P; Valcárcel F
Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Subramanian J; Morgensztern D; Govindan R
Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
[TBL] [Abstract][Full Text] [Related]
13. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
14. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
15. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
Karamitopoulou E; Zlobec I; Panayiotides I; Patsouris ES; Peros G; Rallis G; Lapas C; Karakitsos P; Terracciano LM; Lugli A
Hum Pathol; 2011 Dec; 42(12):1888-96. PubMed ID: 21664646
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
18. Targeting neuropilin 1 as an antitumor strategy in lung cancer.
Hong TM; Chen YL; Wu YY; Yuan A; Chao YC; Chung YC; Wu MH; Yang SC; Pan SH; Shih JY; Chan WK; Yang PC
Clin Cancer Res; 2007 Aug; 13(16):4759-68. PubMed ID: 17699853
[TBL] [Abstract][Full Text] [Related]
19. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
20. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
Int J Oncol; 2007 Apr; 30(4):1019-28. PubMed ID: 17332943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
